Piper Sandler Raises Humana Price Target to $254: Medicare Advantage Strength Supports Bull Case

Piper Sandler analysts have raised the price target for Humana (HUM) to $254, citing the company's strong performance in the Medicare Advantage segment. The analysts note that growth in this area creates a positive bull case for Humana. The price target increase reflects Humana's success in enrollment growth and cost management within its Medicare Advantage plans. Piper Sandler emphasizes the company's potential to expand its market share in this segment, offering a positive outlook for the stock. Analysts state that Humana maintains its competitive advantage in the healthcare sector and that demand for its Medicare Advantage products continues to rise. This supports the company's revenue and profitability expectations. Investors may consider Piper Sandler's revised price target when evaluating Humana's industry position and growth potential. However, factors such as market conditions and regulatory changes could affect stock performance. This is not investment advice.